生活方式干预联合激素避孕药改善多囊卵巢综合征女性性功能障碍
本研究为随机对照试验的二次分析,纳入114例鹿特丹标准诊断的多囊卵巢综合征女性,比较连续口服避孕药、强化生活方式干预及两者联合16周对性功能的影响。结果显示各治疗组FSFI总分及FSDS-R评分均无变化,但生活方式干预和联合治疗组FSFI性欲域评分升高;基线FSFI≤26.55者占28.9%,该亚组经生活方式干预和联合治疗后FSFI评分改善,口服避孕药未改变FSFI评分。
要点
- 多囊卵巢综合征女性性功能障碍患病率高,基线28.9%符合FSFI诊断标准。
- 强化生活方式干预或联合口服避孕药可改善性欲域评分及性功能障碍者FSFI评分。
- 口服避孕药单用未改变FSFI评分,16周内性功能障碍患病率无变化。
核心结论
- 多囊卵巢综合征女性性功能障碍高度流行,强化生活方式干预及联合口服避孕药可能改善性功能,机制可能为多因素。
研究设计与样本
- 随机对照试验的二次分析,纳入114例鹿特丹标准诊断的多囊卵巢综合征女性,来自两个学术医疗中心。
主要发现
- 各治疗组16周后FSFI总分和FSDS-R评分均无变化。
- 生活方式干预和联合治疗组FSFI性欲域评分升高,提示性欲改善。
- 基线FSFI≤26.55者共33例(28.9%),该亚组经生活方式干预和联合治疗后FSFI评分改善。
- 口服避孕药未改变FSFI评分,16周时各组性功能障碍患病率无变化。
关键数值与推荐
- 性功能障碍按FSFI基线评分≤26.55定义,33例(28.9%)符合。
- 干预为连续口服避孕药、强化生活方式干预或两者联合,疗程16周。
临床怎么用
- 对多囊卵巢综合征女性应关注性功能,尤其性欲域。
- 强化生活方式干预或联合口服避孕药可作为改善性功能的可选策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the prevalence of female sexual dysfunction in a well-defined polycystic ovary syndrome (PCOS) population, and to assess the impact of common PCOS treatments on sexual function. DESIGN: Secondary analysis of a randomized controlled trial, oral contraceptive pills and weight loss in PCOS. SETTING: Two academic medical centers. PATIENTS: Women with PCOS (N = 114) defined by the Rotterdam criteria. INTERVENTIONS: Continuous oral contraceptive pill (OCP) or intensive lifestyle modification (Lifestyle) or the combination (Combined) for 16 weeks. MAIN OUTCOME MEASURES: Change in Female Sexual Function Index (FSFI) and Female Sexual Distress Scale-Revised (FSDS-R) scores after 16 weeks. RESULTS: There was no change in total FSFI or FSDS-R score in any treatment group; however, an increase in the FSFI desire domain subscore was observed in the Lifestyle and Combined treatments, indicating improved sexual desire over the 16-week period. Overall, 33 participants (28.9%) met criteria for sexual dysfunction by FSFI criteria (baseline score ≤26.55). Among this group, FSFI score improved after 16 weeks of Lifestyle and Combined treatments. There was no change in prevalence of sexual dysfunction in treatment groups at 16 weeks. Use of OCPs did not alter FSFI scores. CONCLUSION(S): Female sexual dysfunction is highly prevalent among women with PCOS. Our findings suggest that common treatments for PCOS, including intensive lifestyle modification and the combination of intensive lifestyle modification and OCPs, have the potential to improve sexual function in these women; the mechanism for these improvements is likely multifactorial. CLINICAL TRIAL REGISTRATION NUMBER: NCT00704912.
引用
- Steinberg Weiss M, Roe AH, Allison KC, et al. Lifestyle modifications alone or combined with hormonal contraceptives improve sexual dysfunction in women with polycystic ovary syndrome. Fertil Steril. 2020. PMID: 33059886. doi:10.1016/j.fertnstert.2020.08.1396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。